Gestational diabetes as a risk factor for GBS maternal rectovaginal colonization: a systematic review and meta-analysis Vicki Mercado-Evans^{1,2}, Jacob J. Zulk¹, Zainab A. Hameed¹, and Kathryn A. Patras^{1,3*} ¹Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA. ²Medical Scientist Training Program, Baylor College of Medicine, Houston, TX 77030, USA. ³Alkek Center for Metagenomics and Microbiome Research, Baylor College of Medicine, Houston, TX 77030, USA. Corresponding author: K. Patras, PhD, Department of Molecular Virology and Microbiology, Alkek Center for Metagenomics and Microbiome Research, Baylor College of Medicine, One Baylor Plaza, MS 385, Houston, TX, 77030, USA email: katy.patras@bcm.edu, phone: 713-798-5732 Key words: Group B Streptococcus, Streptococcus agalactiae, gestational diabetes, diabetes mellitus, type 1 diabetes, type 2 diabetes, vaginal colonization, neonatal outcomes, vaginal microbiome

46 **ABSTRACT**

47 Background

Maternal rectovaginal colonization by group B Streptococcus (GBS) increases the risk 48 49 of perinatal GBS disease that can lead to death or long-term neurological impairment. Factors that increase the risk of rectovaginal GBS carriage are incompletely understood 50 resulting in missed opportunities for detecting GBS in risk-based clinical approaches. 51 There is a lacking consensus on whether gestational diabetes mellitus (GDM) is a risk 52 53 factor for rectovaginal GBS. This systematic review and meta-analysis aims to address 54 current conflicting findings and determine whether GDM should be clinically considered 55 as a risk factor for maternal GBS colonization.

56

57 Methods

58 Peer-reviewed studies that provided GDM prevalence and documented GBS vaginal 59 and/or rectal colonization in women with and without GDM were included in this 60 analysis.

From study inception to October 30, 2023, we identified 6,275 relevant studies from EMBASE and PUBMED of which 19 were eligible for inclusion. Eligible studies were analyzed and thoroughly assessed for risk of bias with a modified Newcastle-Ottawa Scale that interrogated representativeness and comparability of cohorts, quality of reporting for GDM and GBS status, and potential bias from other metabolic diseases. Results were synthesized using STATA 18 and analyzed using random-effects metaanalyses.

68

69 Results

Studies encompassed 266,706 women from 10 different countries, with study periods spanning from 1981 to 2020. Meta-analysis revealed that gestational diabetes is associated with a 16% increased risk of rectovaginal GBS carriage (OR 1.16, Cl 1.07-1.26, P = 0.003). We also performed subgroup analyses to assess independent effects of pregestational vs. gestational diabetes on risk of maternal GBS carriage. Pregestational diabetes (Type 1 or Type 2 diabetes mellitus) was also associated with an increased risk of 76% (pooled OR 1.76, Cl 1.27-2.45, P = 0.0008).

77

78 Conclusions

This study achieved a consensus among previously discrepant observations and demonstrated that gestational diabetes and pregestational diabetes are significant risk factors for maternal rectovaginal carriage of GBS. Recognition of GDM as a risk factor during clinical decisions about GBS screening and intrapartum antibiotic prophylaxis may decrease the global burden of GBS on maternal-perinatal health.

- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91

92

93 INTRODUCTION

94 Group B Streptococcus (GBS) remains a leading cause of neonatal morbidity and 95 mortality across the globe despite nearly two decades of systematic implementation of preventative approaches that include universal maternal screening or risk-based 96 administration of antibiotics during delivery[1]. GBS colonizes the vaginal and/or 97 gastrointestinal tract of about 18% of pregnant women[2, 3]. Neonates can acquire GBS 98 99 during passage through the vaginal canal during delivery, and GBS also has the 100 capacity to ascend into the uterine-fetal space before parturition. While some women and their neonates are colonized without symptoms, GBS can cause devastating 101 102 complications and disease such as spontaneous abortion, preterm labor, stillbirth, and 103 neonatal sepsis and meningitis[1, 4]. The mechanisms driving the divergence in GBS 104 pathogenic vs. commensal behavior is poorly understood. Currently, the following 105 maternal factors are clinically recognized for increasing the risk of GBS neonatal 106 disease and are used to identify women who should be given intrapartum antibiotic 107 prophylaxis (IAP): 1) previous infant with early-onset GBS disease (EOGBS), 2) GBS bacteriuria during the current pregnancy, 3) temperature > 38 °C during labor, 4) 108 109 prolonged rupture of membranes (PROM) > 18 hours, or 5) delivery at < 37 weeks of 110 gestation[5]. Some countries practice this risk-based approach and others implement 111 universal screening of women around 35 weeks of gestation, with subsequent IAP for those who have rectovaginal GBS carriage. Screening based approaches are 112 associated with enhanced protection against neonatal GBS early onset disease (EOD; 113 114 occurring in the first week of life) compared to risk-based strategies[5], which suggests

that we have yet to understand all of the maternal factors that predict GBS disease.
Additionally, up to 46% of cases of EOD occur in the absence of the risk factors
currently used for clinical decision making[5-7].

118

One possible additional risk factor for maternal rectovaginal GBS colonization is 119 gestational diabetes mellitus (GDM) which affects approximately 14% of pregnancies 120 worldwide[8]. GDM, diabetes that acutely develops during pregnancy, is a state of 121 122 heightened insulin resistance, insufficient pancreatic insulin production, hyperglycemia, 123 immune dysregulation, and altered vaginal microbial composition[9-12]. This systemic 124 disruption to maternal physiology leads to an increased risk of complications including 125 preterm birth, pre-eclampsia, and a long-term increased risk of cardiovascular disease in both women and their children. In clinical cohort studies, infants born to women with 126 127 gestational diabetes are at greater risk of early onset culture-verified GBS sepsis[13], 128 late onset clinical sepsis[14] and extended hospital stay[15]. Considering that 129 rectovaginal GBS carriage is the primary risk factor for GBS neonatal sepsis, women with GDM may have greater GBS colonization rates thereby imparting increased risk of 130 131 neonatal disease. Observational clinical studies have reported conflicting findings on the association between diabetes (pregestational Type 1 or Type 2 and GDM) and GBS 132 carriage; some have found increased risk of GBS colonization[16-21] in diabetic 133 134 pregnant women (pregestational and/or gestational), while others found no 135 association[15, 22, 23]. Several of these studies did not specifically distinguish pregestational (Type 1 or Type 2 DM) from GDM. Although these metabolic diseases 136

share several features, the acuity and specificity to pregnancy of GDM lends uniqueinsight into the pathogenic potential of group B *Streptococcus*.

The aim of this study was to conduct a systematic review and meta-analysis of the risk for rectovaginal GBS carriage in women affected by GDM. Resolving whether GDM is an independent risk factor for maternal GBS colonization is essential for closing the gap in current IAP approaches; a critical step towards reducing the global burden of GBSassociated neonatal morbidity and mortality.

144

145 MATERIALS AND METHODS

146 Search strategy and study selection

Studies were identified through a database search that included PubMed and EMBASE, which encompassed MEDLINE and preprints as sources (**Fig. 1**). The search strategy implemented search terms intended to capture two kinds of studies: 1) Those that specifically assessed GBS maternal colonization and/or neonatal transmission in women with gestational diabetes, and 2) studies on GBS maternal colonization prevalence which included information about gestational diabetic status and respective GBS status.

154

As such, a combination of the following search terms was implemented: gestational diabetes or GDM, chorioamnionitis, newborn and sepsis or cocci and sterile site, and group b streptococcus or GBS or streptococcus agalactiae, English, humans. The following search terms were used as filters followed by the word not: in vitro, ex vivo, animal, tilapia, zebra fish, bovine, breast milk, phylogeny, case study, cells, case report, 160 urinary tract infection, non-pregnancy, endocarditis, murine, mouse, primate. Reviews, 161 conference abstracts and editorials were excluded from our search. The literature search was restricted to human studies published in English, with no study period 162 163 restrictions. The last query was performed on 10/30/2023. Titles and abstracts were screened for adherence to the inclusion and exclusion criteria detailed below. This study 164 was not registered, but the Preferred Reporting Items for Systematic Reviews and 165 Meta-Analyses (PRISMA) was used as a guideline for this systematic review and meta-166 167 analysis.

168

169 Inclusion and exclusion criteria

170 The inclusion criteria for this study were: peer-reviewed studies that documented GBS 171 vaginal and/or rectal colonization in expectant mothers, with information about the 172 proportion of women who were clinically diagnosed with GDM. Studies were required to 173 provide the proportion of women who did not have GDM. We included studies that 174 potentially had women with pregestational diabetes in the control, non-GDM, group but we stratified analyses accordingly. Reporting of GDM diagnosis and maternal GBS 175 176 vaginal and/or rectal colonization was accepted through medical records or diagnosis 177 from medical professionals. Studies were included irrespective of sample type used to determine GBS colonization (vaginal, rectal, or perianal region) and studies employing 178 179 molecular or biochemical detection of GBS were included. Studies with self-collected vaginal swab samples (n = 1) were included. Additionally, observational, baseline data 180 from interventional, case-control, retrospective and prospective, cross sectional and 181 182 cohort studies were all included. The exclusion criteria for this study were: case studies,

183 reviews, or letters to the editor, lack of a GBS negative or non-GDM control group, 184 published in a language other than English, studies that did not explicitly state diabetes type (GDM vs. pregestational diabetes: Type 1 or Type 2 DM), or missing critical 185 186 information such as exclusion/inclusion criteria or GBS and/or GDM prevalence in the 187 study population. For relatively contemporary studies (published in the past decade) that did not specify diabetes type, we emailed corresponding authors to acquire 188 189 information about the number of participants that had GDM vs. Type 1 vs. Type 2 190 diabetes and their GBS status. One reviewer screened titles and abstracts, and three independent reviewers screened full texts to assess studies for eligibility. Reasons for 191 exclusion of each eligible study are provided (Supplemental table 1). 192

193

194 Data extraction and risk of bias assessment

Two independent reviewers extracted data including: study characteristics, the number of participants in each group, and the number of GBS positive and negative cases in GDM, non-GDM and pregestational diabetic populations, odds ratios (OR), GBS detection method, GDM diagnostic criteria, gestational age at time of GBS screen and any relevant findings on maternal and/or neonatal outcomes.

200

All eligible studies were assessed for quality and risk of bias by two independent reviewers via an adapted Newcastle-Ottawa Scale[24] (**Supplemental table 2**) which focused on four broad criteria: 1) How representative the groups were of the greater communities from which the study was conducted, 2) comparability of the groups to each other with respect to various characteristics (maternal age, BMI, racial/ethnic

206 representation, socioeconomic status, etc.), 3) Quality of outcome assessment 207 (ascertainment of GBS and GDM status), and 4) Potential of bias from other metabolic 208 diseases in each group such as obesity and pregestational diabetes (in non-GDM 209 control group). Each assessment category was scored, and the sum was used to 210 determine overall quality and risk of bias for each study. Any discrepancies greater than 211 2 points for any category were resolved via a discussion to achieve consensus. A total 212 score \leq 3 was considered low bias, > 3 and \leq 6 indicated moderate bias, and \geq 6 was 213 classified as high risk of bias.

214

215 Data synthesis and analysis

216 Unadjusted ORs were calculated for studies in which only prevalence data were 217 provided, otherwise reported ORs for GDM or pregestational diabetes were utilized. OR calculation and analysis were performed using STATA 18. To calculate ORs, we 218 219 compared the odds of rectovaginal GBS carriage in women with GDM versus women 220 without GDM. For the sub-analysis of women with pregestational diabetes, we 221 compared the odds of rectovaginal GBS carriage to nondiabetic women, or to women 222 with GDM. For sub-analysis of pregestational diabetes, Piper et al., 1999[15] could not 223 be included because this study accounted for effects of pregestational diabetes by 224 excluding this population entirely from their study. Forest plots display prevalence, 225 individual ORs and 95% confidence intervals (CI) and meta-analysis of pooled ORs with random effects modeling. The I² index was used to assess the impact of study 226 227 heterogeneity on study estimate variance[24], with low, moderate and high heterogeneity indicated by I² of 25%, 50% and 75% respectively[25]. Publication bias 228

was assessed with funnel plots of the ORs (natural logarithm) against the inverse of the standard error and Egger's regression test, with P < 0.05 indicating a significantly asymmetric funnel plot and thus significant publication bias.

232

233 **RESULTS**

234 Study characteristics

235 The initial search identified 6.275 studies, of which 65 articles passed screening and 236 were subjected to full-text assessment for eligibility (Fig. 1). 19 articles with study periods spanning from 1981 to 2020 were eligible based on the aforementioned criteria, 237 238 with exclusion of 46 studies for various reasons (Supplemental table 1). Table 1 239 provides a summary of study characteristics. The total number of women included in 240 this systematic review and meta-analysis is 266,706; there were 18,715 women with 241 GDM, 2,598 with pregestational diabetes, and 195,545 without GDM. The studied 242 populations are representative of many communities across the globe with inclusion of 243 Australia, Brazil, China, Finland, Lebanon, Mexico, Morocco, Nigeria, Spain, and the 244 United States. Of these countries, none were of low-income, three were of lower-middle 245 income, three were of upper-middle income, and four were of high-income as 246 determined by the 2023 World Bank guidelines [26]. 6/19 were multicenter studies and 247 routine screening for GBS colonization and administration guidelines for intrapartum 248 antibiotic prophylaxis (IAP) was not an established practice at the time for 64% of 249 studies. Studies also consisted of a mix of prospective (57%), retrospective (14%), 250 cross-sectional (5%), case-control (14%), and population-based cohort (10%) study 251 designs. Rectovaginal, vaginal and/or perineal GBS carriage was determined by culture

for all studies: 14 studies performed rectovaginal sampling, 3 solely assessed vaginal carriage, and 2 studies did not specify. 5 studies performed culturing and molecular or biochemical identification as recommended by CDC guidelines whereas 14 studies had methods incongruent with guidelines or did not provide enough detail. 6 were found to have low risk of bias, 8 had moderate risk of bias, and 5 had high risk of bias (**Table 1**

and Supplemental table 3).

258 Association between gestational diabetes and maternal GBS colonization

259 A meta-analysis of the association between gestational diabetes and maternal 260 rectovaginal GBS carriage revealed that women with GDM are 16% more likely to be 261 colonized by GBS compared to women without GDM (pooled OR 1.16, CI 1.07-1.26, P = 0.003) (Fig. 2). Heterogeneity of all studies was moderate (I^2 = 34.9, P = 0.02). A 262 263 significant driver of heterogeneity was whether the prevalence of pregestational 264 diabetes was accounted for in the study population; sub-analysis revealed that when pregestational diabetes prevalence was not documented, and possibly present in the 265 266 non-GDM control group, women with GDM had a 43% increased risk of GBS 267 colonization (OR 1.43, CI 1.08-1.9, P = 0.01). Study heterogeneity was significantly greater among this subset of studies ($I^2 = 67.8$, P = 0.02). When pregestational diabetes 268 prevalence is accounted for (thus reliably excluded from the non-GDM control group), 269 270 study heterogeneity is mitigated ($I^2 = 27$, P = 0.10), and women with GDM have a 13% increased risk of GBS colonization compared to the non-diabetic control group (OR 271 272 1.13, CI 1.03-1.24, P = 0.01) (Fig. 2).

273

Association between pregestational diabetes and maternal GBS colonization.

medRxiv preprint doi: https://doi.org/10.1101/2023.11.02.23297989; this version posted November 3, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

275 We performed an additional sub-analysis to determine the independent association 276 between pregestational diabetes and maternal GBS carriage, which revealed that 277 women with pregestational diabetes have a 76% increased risk of rectovaginal GBS 278 carriage compared to non-diabetic women (Fig. 3) (pooled OR 1.76, Cl 1.27-2.45, P = 0.0008). There was a high degree of heterogeneity between studies (I^2 = 78.5%. P = 279 280 Appreciating distinct pathophysiology and outcomes for women with 0.01). 281 pregestational diabetes vs. gestational diabetes, we assessed differences in risk of GBS 282 colonization. There was no significant difference in risk of GBS rectovaginal colonization 283 based on diabetes type (Fig. 4); women with pregestational diabetes had a similar risk 284 of GBS rectovaginal colonization compared to those with gestational diabetes (pooled 285 OR 1.26, CI 0.96-1.66, P = 0.09). Even so, it is possible that differences will resolve with 286 a larger sample size.

287

288 Publication bias and sensitivity analysis

289 Visual assessment of the funnel plot (Fig. 5) shows asymmetrical distribution of studies, 290 with publication bias confirmed by Egger's test (P = 0.005). Sensitivity analysis included complete exclusion of studies that did not document or control for pregestational 291 292 diabetic prevalence and exclusion of studies with high risk of bias. A meta-analysis was 293 then performed on the remaining 8 studies (Raimer, Ramos, Stapleton, Edwards, 294 Furfaro, Manzanares, Place, McCoy). Findings were robust; gestational diabetes was 295 still associated with a 13% increased risk of rectovaginal GBS colonization (OR 1.13, 95% CI 1.02-1.25, P = 0.02), without significant shifts in study heterogeneity ($I^2 = 35.4\%$, 296 297 P = 0.08).

298

299 **DISCUSSION**

300 To our knowledge, this is the first systematic review and meta-analysis examining the 301 association between gestational diabetes mellitus and group B streptococcal 302 rectovaginal colonization. We also performed subgroup analyses to assess independent 303 effects of pregestational vs. gestational diabetes on risk of maternal GBS carriage. Our 304 meta-analysis demonstrates that women with GDM have a significant 16% greater risk 305 of being colonized by GBS, which may in part explain the increased risk of sepsis for 306 neonates born to mothers with GDM[13, 14]. Sub-analysis revealed that women pregestational diabetes have a 71% increased risk. There were no differences in risk 307 308 based on diabetes type, which agrees with observations from prior cohort studies[17, 309 18].

310

311 GDM-mediated perturbations to critical host defenses such as immunity and the vaginal 312 microbiota may mechanistically contribute to this increased susceptibility to GBS 313 carriage. GDM leads to altered neutrophil, NK, T cell and macrophage abundance and/or activity both in the peripheral blood and at the maternal-fetal interface[10, 41-44]. 314 315 While the direct role of the vaginal microbiome in propagating or limiting GBS 316 colonization remains largely unknown, it is well-appreciated that members of the vaginal 317 microbiota play direct and indirect roles in maintaining reproductive health and 318 pregnancy outcomes and Lactobacillus dominance is considered a hallmark of an optimal vaginal community[45-49]. During pregnancy, the stability of the vaginal 319 320 microbiota increases with Lactobacillus enrichment and overall lower alpha diversity[50,

medRxiv preprint doi: https://doi.org/10.1101/2023.11.02.23297989; this version posted November 3, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

321 51]. In non-diabetic pregnancy, non-Lactobacillus dominance or dominance by 322 Lactobacillus gasseri has been associated with increased risk of GBS colonization[40, 323 52]. GDM disrupts the vaginal microbiota with increased diversity and enrichment of 324 nonoptimal members including Bacteroides, Klebsiella, Enterococcus, and Enterobacter 325 and Staphylococcus[11, 12, 53], of which Staphylococcus has been positively 326 associated with vaginal GBS colonization[54]. Microbial communities inherited by 327 neonates are also impacted by GDM reflected by increased colonization by 328 Streptococcaceae and Enterococcaceae which may contribute to worse neonatal 329 outcomes upon GBS encounter[11, 55, 56]. Indeed, in a preclinical model of GDM, we recently showed that GDM susceptibility to fetoplacental infection was driven by 330 331 perturbations to maternal immunity and vaginal microbial communities in addition to 332 pathogenic bacterial adaptations[57].

333

334 The heterogeneity observed in the 19 studies representing 10 different countries were in 335 part explained by the presence of pregestational diabetes as a potential confounder, as 336 revealed by sub-analyses. Other possible drivers of heterogeneity are differences in study populations including: sample size, severity of diabetes, discrepancies in access 337 338 to prenatal care thereby impacting who was included in hospital or clinic-based studies, 339 differential presence of confounding metabolic disease such as obesity, variation in 340 inclusive representation of underrepresented or under-resourced communities, and 341 geographical variation in GBS prevalence[1]. Differences in severity of diabetes may also explain variation between studies; a recent study found that pregnant women with 342 343 better glycemic control (Hemoglobin A1c < 6.5%) had a 45% decreased risk of GBS

rectovaginal colonization[58]. However, a few studies report contrasting evidence; two reports found no differences in GBS colonization status for pregnant women requiring insulin therapy[59, 60], and another study found no differences in GBS status between pregnant diabetic women requiring greater than 20 U insulin therapy vs. those requiring less than 20 U per day[61]. Thus, the association between maternal GBS colonization and diabetes severity as indicated by glycemic control and medical management (insulin treatment vs. lifestyle modification) requires further study.

351

352 Notable limitations of some of the studies incorporated in this analysis include a lack of 353 information about GDM or pregestational diabetic severity (e.g. HbA1C or need for 354 medical intervention), unstated GDM diagnostic criteria, potential confounding by other 355 metabolic disorders such as obesity, and limited description of GBS detection 356 techniques (although this was a minority of studies). However, these factors were taken 357 into consideration in our assessment of study quality and bias risk. The presence of 358 publication bias is another limitation and may mean that the risk is overestimated as 359 studies with negative findings are less likely to be published. Nevertheless, sensitivity analysis revealed that the association between GDM and GBS carriage remains when 360 361 high-risk and potentially confounding studies are excluded. Thus, we are confident that 362 our findings withstand the observed limitations.

363

364 CONCLUSIONS

Ultimately, this systematic review and meta-analysis of 19 studies representing over
260,000 women across the globe revealed gestational diabetes as a novel risk factor for

maternal rectovaginal colonization by group B *Streptococcus*. Considering that up to 46% of neonates with GBS invasive disease are born to women with no currently recognized risk factors for GBS transmission, GDM may be an important risk that is not yet clinically recognized. Ultimately, expanding our knowledge of additional risk factors for GBS neonatal transmission and disease will improve strategies for screening, preventing, and treating fetal and neonatal GBS morbidity and mortality.

373

374 LIST OF ABBREVIATIONS

- 375 GBS: Group B Streptococcus
- 376 IAP: Intrapartum antibiotic prophylaxis
- 377 EOGBS: Early-onset GBS disease
- 378 GDM: Gestational diabetes mellitus
- 379

380 **DECLARATIONS**

381 Availability of data and materials

- 382 The datasets supporting the conclusions of this article are included within the article,
- and in the cited studies included in the meta-analysis.
- 384

385 Competing interests

- 386 The authors declare that they have no competing interests.
- 387
- 388 Funding

389 VME and JZ were supported by NIH F31 awards (AI167547, DK136201-01) 390 respectively. VME was also supported by a scholarship from Baylor Research 391 (BRASS) Advocates for Student Scientists and а Grant for Emerging 392 Researchers/Clinicians Mentorship [58] Program from the Infectious Diseases Society 393 of America (IDSA). JJZ was supported by an NIH T32 award (T32GM136554). Studies 394 were supported by a Burroughs Wellcome Fund Next Gen Pregnancy Initiative 395 (NGP10103), NIH R01 (DK128053), and R21 (AI173448) to KAP. 396

- 397 Authors' contributions
- 398 KAP and VME conceived and designed the study. VME, JJZ, and ZH, performed

399 systematic review and analyses. VME and KAP analyzed data and interpreted results.

400 KAP secured funding. VME and KAP drafted the manuscript. All authors reviewed and

401 edited the manuscript.

402

403 **REFERENCES**

404

- Gonçalves BP, Procter SR, Paul P, Chandna J, Lewin A, Seedat F, Koukounari A, Dangor Z, Leahy S, Santhanam S *et al*: Group B streptococcus infection during pregnancy and infancy: estimates of regional and global burden. *Lancet Glob Health* 2022, **10**(6):e807-e819.
- Kwatra G, Cunnington MC, Merrall E, Adrian PV, Ip M, Klugman KP, Tam WH,
 Madhi SA: Prevalence of maternal colonisation with group B streptococcus:
 a systematic review and meta-analysis. Lancet Infect Dis 2016, 16(9):10761084.
- 413 3. Russell NJ, Seale AC, O'Driscoll M, O'Sullivan C, Bianchi-Jassir F, Gonzalez-Guarin J. Lawn JE. Baker CJ. Bartlett L. Cutland C et al: Maternal Colonization 414 With Group B Streptococcus and Serotype Distribution Worldwide: 415 416 **Systematic** Review and Meta-analyses. Clin Infect Dis 2017. 65(suppl 2):S100-s111. 417
- 418 4. Schrag SJ, Farley MM, Petit S, Reingold A, Weston EJ, Pondo T, Hudson Jain J,
 419 Lynfield R: Epidemiology of Invasive Early-Onset Neonatal Sepsis, 2005 to
 420 2014. Pediatrics 2016, 138(6).

- 421 5. Hasperhoven GF, Al-Nasiry S, Bekker V, Villamor E, Kramer B: Universal
 422 screening versus risk-based protocols for antibiotic prophylaxis during
 423 childbirth to prevent early-onset group B streptococcal disease: a
 424 systematic review and meta-analysis. *Bjog* 2020, **127**(6):680-691.
- Heath PT, Balfour GF, Tighe H, Verlander NQ, Lamagni TL, Efstratiou A: Group
 B streptococcal disease in infants: a case control study. Arch Dis Child
 2009, 94(9):674-680.
- Trijbels-Smeulders M, de Jonge GA, Pasker-de Jong PC, Gerards LJ, Adriaanse
 AH, van Lingen RA, Kollée LA: Epidemiology of neonatal group B
 streptococcal disease in the Netherlands before and after introduction of
 guidelines for prevention. Arch Dis Child Fetal Neonatal Ed 2007, 92(4):F271276.
- 8. Wang H, Li N, Chivese T, Werfalli M, Sun H, Yuen L, Hoegfeldt CA, Elise Powe
 C, Immanuel J, Karuranga S *et al*: IDF Diabetes Atlas: Estimation of Global
 and Regional Gestational Diabetes Mellitus Prevalence for 2021 by
 International Association of Diabetes in Pregnancy Study Group's Criteria.
 Diabetes Res Clin Pract 2022, 183:109050.
- 438 9. McIntyre HD, Catalano P, Zhang C, Desoye G, Mathiesen ER, Damm P:
 439 Gestational diabetes mellitus. Nat Rev Dis Primers 2019, 5(1):47.
- McElwain CJ, McCarthy FP, McCarthy CM: Gestational Diabetes Mellitus and
 Maternal Immune Dysregulation: What We Know So Far. Int J Mol Sci 2021,
 22(8).
- Wang J, Zheng J, Shi W, Du N, Xu X, Zhang Y, Ji P, Zhang F, Jia Z, Wang Y *et al*. **Dysbiosis of maternal and neonatal microbiota associated with gestational diabetes mellitus**. *Gut* 2018, **67**(9):1614-1625.
- 446 12. Cortez RV, Taddei CR, Sparvoli LG, Ângelo AGS, Padilha M, Mattar R, Daher S:
 447 Microbiome and its relation to gestational diabetes. Endocrine 2019,
 448 64(2):254-264.
- Håkansson S, Källén K: Impact and risk factors for early-onset group B
 streptococcal morbidity: analysis of a national, population-based cohort in
 Sweden 1997-2001. Bjog 2006, 113(12):1452-1458.
- 452 14. Medugu N, Iregbu KC, Parker RE, Plemmons J, Singh P, Audu LI, Efetie E, 453 Davies HD, Manning SD: Group B streptococcal colonization and 454 transmission dynamics in pregnant women and their newborns in Nigeria: 455 implications for prevention strategies. *Clinical Microbiology and Infection* 456 2017, 23(9):673.e679-673.e616.
- 457 15. Piper JM, Georgiou S, Xenakis EM, Langer O: Group B streptococcus infection rate unchanged by gestational diabetes. Obstet Gynecol 1999, 93(2):292-296.
- 460
 461
 461
 461
 462
 462
 463
 463
 464
 465
 465
 466
 466
 466
 466
 467
 468
 468
 469
 469
 469
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 461
 461
 462
 463
 463
 464
 464
 465
 465
 465
 466
 466
 467
 467
 468
 468
 469
 469
 469
 460
 460
 460
 460
 460
 460
 460
 460
 460
 461
 461
 462
 463
 463
 464
 465
 465
 466
 466
 467
 467
 468
 468
 468
 469
 469
 469
 469
 469
 460
 460
 460
 460
 461
 461
 462
 463
 463
 464
 465
 465
 466
 466
 467
 467
 468
 468
 468
 469
 469
 469
 469
 469
 469
 469
 469
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
 460
- 464 17. Matorras R, Garcia-Perea A, Usandizaga JA, Omenaca F: Recto-vaginal
 465 colonization and urinary tract infection by group B streptococcus in the

466 pregnant diabetic patient. Acta Obstetricia et Gynecologica Scandinavica 1988,
467 67(7):617-620.

- Ramos E, Gaudier FL, Hearing LR, Del Valle GO, Jenkins S, Briones D: Group B
 streptococcus colonization in pregnant diabetic women. Obstet Gynecol
 1997, 89(2):257-260.
- 471 19. Bey M, Pastorek li JG, Miller Jr JM: Group B streptococcal colonization in the
 diabetic gravida patient. American Journal of Perinatology 1992, 9(5-6):425473 427.
- Chen X, Cao S, Fu X, Ni Y, Huang B, Wu J, Chen L, Huang S, Cao J, Yu W, Ye
 H: The risk factors for Group B Streptococcus colonization during
 pregnancy and influences of intrapartum antibiotic prophylaxis on maternal
 and neonatal outcomes. *BMC Pregnancy Childbirth* 2023, 23(1):207.
- 478 21. Farideh A, Abdolkarim H, Naderi Nasab M: Comparison of Group B
 479 Streptococcal Colonization in the Pregnant Diabetic and Non-Diabetic
 480 Women. Acta Medica Iranica 2007, 47(2).
- 481 22. Siqueira F, Ferreira EM, de Matos Calderon I, Dias A: Prevalence of colonisation by group B streptococcus in pregnant patients in Taguatinga,
 483 Federal District, Brazil: a cross-sectional study. Arch Gynecol Obstet 2019,
 484 299(3):703-711.
- Lukic A, Napoli A, Santino I, Bianchi P, Nobili F, Ciampittiello G, Nardone MR,
 Santomauro M, Di Properzio M, Caserta D: Cervicovaginal bacteria and fungi
 in pregnant diabetic and non-diabetic women: a multicenter observational
 cohort study. Eur Rev Med Pharmacol Sci 2017, 21(10):2303-2315.
- 489 24. Higgins JP, Áltman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J,
 490 Schulz KF, Weeks L, Sterne JA: The Cochrane Collaboration's tool for
 491 assessing risk of bias in randomised trials. *Bmj* 2011, 343:d5928.
- Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat
 Med 2002, 21(11):1539-1558.
- 49426.2022-2023WorldBankCountryLendingGroupguidelines495[https://worldpopulationreview.com/country-rankings/middle-income-countries]
- Raimer K, O'Sullivan MJ: Influence of diabetes on group B Streptococcus
 colonization in the pregnant patient. *J Matern Fetal Med* 1997, 6(2):120-123.
- 498 28. Stapleton RD, Kahn JM, Evans LE, Critchlow CW, Gardella CM: Risk factors for
 499 group B streptococcal genitourinary tract colonization in pregnant women.
 500 Obstet Gynecol 2005, 106(6):1246-1252.
- 501 29. Chen J, Fu J, Du W, Liu X, Rongkavilit C, Huang X, Wu Y, Wang Y, McGrath E:
 502 Group B streptococcal colonization in mothers and infants in western
 503 China: Prevalences and risk factors. BMC Infectious Diseases 2018, 18(1).
- 30. Moraleda C, Benmessaoud R, Esteban J, López Y, Alami H, Barkat A, Houssain
 T, Kabiri M, Bezad R, Chaacho S *et al*: Prevalence, antimicrobial resistance
 and serotype distribution of group B streptococcus isolated among
 pregnant women and newborns in Rabat, Morocco. Journal of Medical
 Microbiology 2018, 67(5):652-661.
- 509 31. Dai W, Zhang Y, Xu Y, Zhu M, Rong X, Zhong Q: The effect of group B
 510 streptococcus on maternal and infants' prognosis in Guizhou, China.
 511 Bioscience Reports 2019, 39(12).

- 512 32. Furfaro LL, Nathan EA, Chang BJ, Payne MS: Group B streptococcus
 513 prevalence, serotype distribution and colonization dynamics in Western
 514 Australian pregnant women. Journal of Medical Microbiology 2019, 68(5):728515 740.
- Ji Y, Zhao C, Ma XX, Peppelenbosch MP, Ma Z, Pan Q: Outcome of a
 screening program for the prevention of neonatal early-onset group B
 Streptococcus infection: A population-based cohort study in inner
 Mongolia, China. Journal of Medical Microbiology 2019, 68(5):803-811.
- Manzanares S, Zamorano M, Naveiro-Fuentes M, Pineda A, Rodríguez-Granger
 J, Puertas A: Maternal obesity and the risk of group B streptococcal
 colonisation in pregnant women. Journal of Obstetrics and Gynaecology 2019,
 39(5):628-632.
- 35. Zhu Y, Huang J, Lin XZ, Chen C: Group B Streptococcus Colonization in Late
 Pregnancy and Invasive Infection in Neonates in China: A Population Based 3-Year Study. Neonatology 2019, 115(4):301-309.
- 36. Alfouzan W, Gaddar N, Dhar R, Rabaan AA: A study of group B streptococcus
 in pregnant women in Lebanon: Prevalence, risk factors, vaginal flora and
 antimicrobial susceptibility. Infezioni in Medicina 2021, 29(1):85-93.
- Huang J, Zheng L, Su Y, Wang F, Kong H, Chang Y, Xin H: Effects of group B
 streptococcus infection on vaginal micro-ecology and pregnancy
 outcomes of pregnant women in late pregnancy. European Journal of
 Obstetrics and Gynecology and Reproductive Biology 2021, 267:274-279.
- 38. Place K, Rahkonen L, Nupponen I, Kruit H: Vaginal streptococcus B
 colonization is not associated with increased infectious morbidity in labor
 induction. Acta Obstetricia et Gynecologica Scandinavica 2021, 100(8):15011510.
- 538 39. Del Carmen Palacios-Saucedo G, Rivera-Morales LG, Vazquez-Guillen JM,
 539 Caballero-Trejo A, Mellado-Garcia MC, Flores-Flores AS, Gonzalez-Navarro JA,
 540 Herrera- Rivera CG, Osuna-Rosales LE, Hernandez-Gonzalez JA *et al*:
 541 Genomic analysis of virulence factors and antimicrobial resistance of
 542 group B Streptococcus isolated from pregnant women in northeastern
 543 Mexico. *PLoS ONE* 2022, **17**(3 March).
- McCoy JA, Burris HH, Gerson KD, McCarthy C, Ravel J, Elovitz MA:
 Cervicovaginal Microbial-Immune State and Group B Streptococcus
 Colonization in Pregnancy. Am J Perinatol 2023.
- 547 41. Stoikou M, Grimolizzi F, Giaglis S, Schäfer G, van Breda SV, Hoesli IM, Lapaire
 548 O, Huhn EA, Hasler P, Rossi SW, Hahn S: Gestational Diabetes Mellitus Is
 549 Associated with Altered Neutrophil Activity. Front Immunol 2017, 8:702.
- Hara Cde C, França EL, Fagundes DL, de Queiroz AA, Rudge MV, HonorioFrança AC, Calderon Ide M: Characterization of Natural Killer Cells and
 Cytokines in Maternal Placenta and Fetus of Diabetic Mothers. J Immunol
 Res 2016, 2016:7154524.
- 43. Mihalic Z, Kindler O, Raftopoulou S, Santiso A, Wadsack C, Heinemann A, Kargl
 J: Gestational diabetes mellitus dysregulates the PD-1/PD-L1 axis at the
 feto-maternal interface. *bioRxiv* 2023:2023.2001.2025.525478.

- Kang YE, Yi HS, Yeo MK, Kim JT, Park D, Jung Y, Kim OS, Lee SE, Kim JM, Joung KH *et al*: Increased Pro-Inflammatory T Cells, Senescent T Cells, and Immune-Check Point Molecules in the Placentas of Patients With Gestational Diabetes Mellitus. *J Korean Med Sci* 2022, 37(48):e338.
- 45. Greenbaum S, Greenbaum G, Moran-Gilad J, Weintraub AY: Ecological
 dynamics of the vaginal microbiome in relation to health and disease. Am J
 Obstet Gynecol 2019, 220(4):324-335.
- 46. Dunlop AL, Satten GA, Hu YJ, Knight AK, Hill CC, Wright ML, Smith AK, Read
 TD, Pearce BD, Corwin EJ: Vaginal Microbiome Composition in Early
 Pregnancy and Risk of Spontaneous Preterm and Early Term Birth Among
 African American Women. Front Cell Infect Microbiol 2021, 11:641005.
- Tabatabaei N, Eren AM, Barreiro LB, Yotova V, Dumaine A, Allard C, Fraser WD:
 Vaginal microbiome in early pregnancy and subsequent risk of
 spontaneous preterm birth: a case-control study. *Bjog* 2019, **126**(3):349-358.
- 48. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, Karlebach S,
 Gorle R, Russell J, Tacket CO *et al*: Vaginal microbiome of reproductive-age
 women. *Proc Natl Acad Sci U S A* 2011, 108 Suppl 1(Suppl 1):4680-4687.
- 574 49. Zhou X, Bent SJ, Schneider MG, Davis CC, Islam MR, Forney LJ:
 575 Characterization of vaginal microbial communities in adult healthy women using cultivation-independent methods. *Microbiology (Reading)* 2004, 150(Pt 8):2565-2573.
- 578 50. Freitas AC, Chaban B, Bocking A, Rocco M, Yang S, Hill JE, Money DM: The
 vaginal microbiome of pregnant women is less rich and diverse, with lower
 prevalence of Mollicutes, compared to non-pregnant women. Sci Rep 2017,
 581 7(1):9212.
- 582 51. DiGiulio DB, Callahan BJ, McMurdie PJ, Costello EK, Lyell DJ, Robaczewska A,
 583 Sun CL, Goltsman DS, Wong RJ, Shaw G *et al*: Temporal and spatial variation
 584 of the human microbiota during pregnancy. *Proc Natl Acad Sci U S A* 2015,
 585 112(35):11060-11065.
- 586 52. Rosen GH, Randis TM, Desai PV, Sapra KJ, Ma B, Gajer P, Humphrys MS,
 587 Ravel J, Gelber SE, Ratner AJ: Group B Streptococcus and the Vaginal
 588 Microbiota. J Infect Dis 2017, 216(6):744-751.
- 589 53. Rafat D, Singh S, Nawab T, Khan F, Khan AU, Khalid S: Association of vaginal
 590 dysbiosis and gestational diabetes mellitus with adverse perinatal
 591 outcomes. Int J Gynaecol Obstet 2022, 158(1):70-78.
- 592 54. Shabayek S, Abdellah AM, Salah M, Ramadan M, Fahmy N: Alterations of the vaginal microbiome in healthy pregnant women positive for group B
 594 Streptococcus colonization during the third trimester. BMC Microbiol 2022, 22(1):313.
- 596 55. He Z, Wu J, Xiao B, Xiao S, Li H, Wu K: The Initial Oral Microbiota of
 597 Neonates Among Subjects With Gestational Diabetes Mellitus. Front Pediatr
 598 2019, 7:513.
- 599 56. Chen T, Qin Y, Chen M, Zhang Y, Wang X, Dong T, Chen G, Sun X, Lu T, White 600 RA, 3rd *et al*: **Gestational diabetes mellitus is associated with the neonatal** 601 **gut microbiota and metabolome**. *BMC Med* 2021, **19**(1):120.

- Mercado-Evans V, Mejia ME, Zulk JJ, Ottinger S, Hameed Z, Serchejian C,
 Marunde MG, Robertson CM, Ballard MB, Korotkova N *et al*: Gestational
 diabetes augments group B Streptococcus perinatal infection
 through disruptions in maternal immunity and the vaginal microbiota. *bioRxiv* 2023:2023.2006.2023.546252.
- Field C, Bank TC, Spees CK, Germann K, Landon MB, Gabbe S, Grobman WA,
 Costantine MM, Venkatesh KK: Association between glycemic control and
 group B streptococcus colonization among pregnant individuals with
 pregestational diabetes. Am J Reprod Immunol 2023, 90(4):e13779.
- 611 59. Ramos E, Gaudier FL, Hearing LR, Del Valle GO, Jenkins S, Briones D: Group B
 612 streptococcus colonization in pregnant diabetic women. Obstetrics and
 613 Gynecology 1997, 89(2):257-260.
- 60. Pykało-Gawińska D, Zaręba-Szczudlik J, Gawiński C, Stępień A, Dobrowolska Redo A, Malinowska-Polubiec A, Romejko-Wolniewicz E: Gestational weight
 gain and glycemic control in GDM patients with positive genital culture.
 Taiwanese Journal of Obstetrics and Gynecology 2021, 60(2):262-265.
- 618 61. Bey M, Pastorek JG, 2nd, Miller JM, Jr.: **Group B streptococcal colonization in** 619 **the diabetic gravida patient**. *Am J Perinatol* 1992, **9**(5-6):425-427.
- 620
- 621 622
- 623
- 624 625

626 FIGURE LEGENDS

627

628 Figure 1: Study identification, screening, and selection process. Flow diagram of

629 selection of the included studies.

630

631 Figure 2: Association of gestational diabetes and GBS rectovaginal colonization.

Forest plot of the association between gestational diabetes and GBS rectovaginal colonization presented as Odds Ratios (OR) for each study and respective 95% confidence intervals (CI). Studies are grouped by those that did not document (top) or did document (bottom) the prevalence of pregestational diabetes in their study population. The number of women with (GBS+) and without (GBS-) rectovaginal GBS carriage are presented for each study. The dotted black line demarcates no effect (OR =

1). The OR of individual studies are represented by light purple diamonds with shape
size corresponding to the weight of the study as determined by random-effects
modeling, and the paired horizontal lines indicate the 95% Cl. Pooled ORs for each
group are shown by the dark purple diamonds and the orange symbol represents the
OR for all studies.

643

644 Figure 3: Association of pregestational diabetes and GBS rectovaginal 645 colonization. Forest plot of the association between pregestational diabetes and GBS rectovaginal colonization presented as Odds Ratios (OR) for each study and respective 646 647 95% confidence intervals (CI). The number of women with (GBS+) and without (GBS-) 648 rectovaginal GBS carriage are presented for each study. The dotted black line 649 demarcates no effect (OR = 1). The OR of individual studies are represented by blue 650 circles with shape size corresponding to the weight of the study as determined by 651 random-effects modeling, and the paired horizontal lines indicate the 95% CI. Pooled ORs for each group are shown by the dark blue diamond. 652

653

Figure 4: Comparison of diabetes types and associations with GBS rectobaginal colonization. Forest plot of the association between pregestational diabetes and GBS rectovaginal colonization relative to women with gestational diabetes, presented as Odds Ratios (OR) for each study and respective 95% confidence intervals (CI). The number of women with (GBS+) and without (GBS-) rectovaginal GBS carriage are presented for each study. The dotted black line demarcates no effect (OR = 1). The OR of individual studies are represented by squares with shape size corresponding to the

weight of the study as determined by random-effects modeling, and the paired
horizontal lines indicate the 95% CI. Pooled ORs for each group are shown by the dark
beige symbol.

664

Figure 5: Risk of bias of included studies. Funnel plot for visual assessment of publication bias for all included studies. Circles represent individual study estimates (log odds ratio) against the respective standard error. The purple vertical line indicates the pooled OR. The gray lines mark the bounds of a pseudo 95% confidence interval.

671

Table 1: Characteristics of studies included in this systematic review of the association between gestational
 diabetes and rectovaginal GBS colonization.

674

Author, year	Study period	Country	Study Design	Inclusion (I) & Exclusion (E) Criteria	Mean age (SD)	GDM diagnostic criteria and ascertainment	GBS detection method	Potential confounders	Risk of bias
Matorras, 1988[17]	1981-1985	Spain	Prospective	Women randomly selected. No criteria specified.	28.0 (6.1)	Oral GTT around 20 w. Coustan & Lewis Criteria. Pregestational diabetes based on history of diabetes or fasting glycemia >140mg/100mL.	Rectal and vaginal swabs followed by culture detection.	Of the 1,050 patients, 729 had complications that were not specified.	High
Raimer, 1997[27]	11 months but year is not reported	USA	Case- control	I: All pregnant women presenting to the clinic. E: HIV+, history of substance abuse, current STD.	Diabetic 30.6 (6.2) non- diabetic 28.5 (6.8) (<i>P</i> = 0.02)	Oral GTT 24-28 w, considered normal below 140mg/dL, abnormal screen (50 g challenge) was followed by 3h GTT (100g), two elevated values considered abnormal.	Vaginal swab followed by culture detection.	Significant difference in maternal age between diabetic and control groups.	Moderat e
Ramos, 1997[18]	January 1995- March 1996	USA	Prospective	I: Singleton gestation, intact membranes at enrollment, otherwise uncomplicated pregnancy. E: HIV+, chronic	Diabetic 27.0 (6.5) non- diabetic 24.6+/- (6.4)	Oral GTT 24-28 w. At least 2 abnormal readings: fasting glucose greater than or equal to 105 mg/dL, 1h	Rectal and vaginal swabs followed by culture detection.	N/A. Regression analyses controlled for maternal age, race, and obesity.	Low

medRxiv preprint doi: https://doi.org/10.1101/2023.11.02.23297989; this version posted November 3, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

				steroid therapy, cervical incompetence, multifetal gestation.	(<i>P</i> = 0.02)	glucose (50g challenge) greater than or equal to 190 mg/dL, 2h glucose greater than or equal to 165 mg/dL, 3h glucose greater than or equal to 145 mg/dL.			
Piper et al., 1999[15]	January 1992-June 1994 (diabetic cohort); April 1992- December 1992 (nondiabet ic cohort)	USA	Prospective	E: Women with previously affected infants and/or pregestational diabetes.	GDM 28.5 (6.2) Non- diabetic 23.6 (5.5) (<i>P</i> <0.05)	Abnormal glucose tolerance test with universal screening.	Rectovagin al swab followed by culture detection.	Diabetic cohort was significantly older, of higher parity, and less likely to deliver vaginally compared to nondiabetic controls.	High
Stapleton et al., 2005[28]	1997-2002	USA	Case- control	I: All singleton gestation births in Washington State. E: Patients with missing data.	Cases 27.6 (6.1) Controls 27.4 (6.2)	Data extracted from hospital records.	ICD codes for confirmed GBS maternal colonizatio n or suspected carrier.	As acknowledged by authors, risk of disease misclassificati on and cannot distinguish women who were truly GBS negative vs. those who were not screened.	Low


Medugu et al., 2017[14]	May- Septembe r 2014	Nigeria	Prospective	I: Third trimester. E: Multifetal gestation, placenta previa, or elective caesarean section.	29.8 (5)	Interviews, questionnaires, and hospital records.	Vaginal and rectal swabs and culture detection with confirmatio n via PathoDxtra Strep Grouping kit.	Prevalence and effects of comorbidities were not considered.	Moderat e
Chen et al., 2018[29]	January- June 2017	Wester n China	Prospective	 I: >35 w gestation routine prenatal care or at the time of delivery. E: Multifetal gestation, GBS culture results not available. 	Not reported.	Data extracted from hospital records.	Vaginal and rectal swabs and culture and biochemica I detection.	Prevalence of pregestational diabetes not reported, nor other indicators of metabolic stress (BMI).	Low
Moraleda et al., 2018[30]	March- July 2013	Morocc o	Prospective	I: 35-37 w who attended general or high-risk prenatal visits. High risk included pre-existing chronic conditions, complications in previous pregnancies, or maternal, fetal, or placental risks in current pregnancy, or women enrolled at time of delivery without membrane rupture or hemorrhage. No exclusion criteria described.	27 +/- 6.15	Demographic, socio-economic, and clinical data collected through standardized questionnaires.	Recto- vaginal swabs and culture detection.	Control group might contain women with pregestational diabetes as this was not mentioned in exclusion criteria and prevalence of pregestational diabetes in GBS carriers and non- carriers was not described.	High

Dai et al., 2019[31]	Not reported	China	Prospective	I: Native (Chinese), 20-46 years old, 35- 37 w, no sexual intercourse or antibiotic application within recent 3 months. No exclusion criteria described.	GBS+ 30.04 (3.22) GBS- 30.67 (3.51)	Not reported.	Recto- vaginal swabbing followed by PCR on extracted DNA within 24 hours of collection.	Very strict inclusion criteria and did not assess prevalence of pregestational diabetes, nor differences in BMI.	High
Edwards et al., 2019[16]	January 1, 2003 - December 31, 2015	USA	Retrospecti ve cohort	All pregnant women during the timeframe were eligible. No exclusions.	GBS+ 28.0 (6.2) GBS- 28.7 (6.2)	ICD codes from hospital records.	Used diagnostic codes from any time during pregnancy to determine positivity.		Low
Furfaro et al., 2019[32]	2015-2017	Australi a	Prospective cohort	I: 16+ years old, Nulliparous/multiparo us, Gestational age of less than 22 w at enrollment, understand, read, and speak English. E: Highly dependent on medical care, cognitive impairment/intellectu al disability, illegal drug use, antibiotic/antifungal use within 2 weeks of sample collection, multiple pregnancy (twins, etc.).	32 (16- 50)	Not reported.	Self-recto- vaginal swabbing with two swabs at each site. One swab used for multiplex PCR and the other for culture detection.		Low

Ji et al., 2019[33]	January 2016 - December 2016	China	Population- based cohort	I: All pregnant women were screened at 35-37 w, but prior to 35 w were also tested if delivery occurred before then. E: Women whose pregnancy did not result in labor.	Not provided	Hospital records.	Recto- vaginal swab performed by physician followed by RT-PCR and culture detection.		Moderat e
Manzanar es et al., 2019[34]	2012-2014	Spain	Case- Control	 I: Delivery of a single live fetus after 26 w, BMI and GBS culture results available. E: Stillbirth, or less than 26 w. 	GBS+ 30.84 (5.8) GBS- 30.61 (5.66)	Not reported.	Positive culture from a recto- vaginal swab at 35- 37 w or GBS bacteriuria any time during pregnancy.	Urine screening replaced culture if positive any time during pregnancy, no description of culture methods.	Moderat e
Zhu et al., 2019[35]	April 1, 2014 - March 31, 2017	China	Retrospecti ve cohort (population based)	 I: Pregnant women 35-37 w of gestation or with preterm delivery who submitted vaginal swabs. E: Women who did not undergo GBS screening, prenatal diagnosis of fetal malformation, greater or equal to three prior abortions, antibiotic usage in the week prior to admission. 	GBS+ 29.7 (4.30) GBS- 29.51 (4.32)	Questionnaire	Vaginal swabs followed by culture on chromogen ic agar. Neonates were screened by tracheal secretion, gastric fluid, and blood sample culture.	Rectal swabs were not collected, no PCR was performed.	Moderat e

Alfouzan et al., 2021[36]	Not reported	Lebano n	Prospective cross- sectional	Not reported.	Not reported.	Questionnaire utilized to gather sociodemograp hic and clinical information.	Vaginal swabs followed by culture detection.	Control group might include women with pregestational diabetes. Only vaginal swabs were collected which may underestimate GBS colonization.	Moderat e
Huang et al., 2021[37]	June 2019- December 2020	China	Prospective	I: No vaginal GBS colonization before pregnancy, single gestation, viable fetus, no antibiotic use during pregnancy, no sexual activity for 3 days preceding sample collection and no vaginally administered drugs or vaginal lavages 2 weeks before sample collection. E: Malignant tumor, infectious diseases, comorbidities involving heart, liver lungs and other organs, genital tract malformation or incomplete medical records.	Not reported.	Determined from medical records.	Vaginal and rectal swabs followed by PCR detection.	Control group might include women with pregestational diabetes.	Moderat

Place et al., 2021[38]	January 2014- December 2017	Finland	Retrospecti ve	I: Women undergoing labor induction, singleton gestation, cephalic presentation, unfavorable cervix, intact amniotic membranes. E: Women for which GBS testing was indeterminant.	31.4 (5.4)	2 hour 75 g oral glucose tolerance test.	Vaginal and rectal swabs PCR detection (Xpert GBS).	All women in this study had an unfavorable cervix.	Moderat e
Del Carmen Palacios- Saucedo, et al, 2022[39]	April 2017 - December 2018	Mexico	Prospective	Not reported.	Median and range of GBS colonize d: 25 (19-37), median and range of non- colonize d: 27 (14-43)	Not reported.	Recto- vaginal swabbing followed by culture and biochemica I identificatio n.	No definition of GDM.	High
McCoy et al., 2023[40]	December 2013- February 2017	USA	Secondary analysis of prospective cohort study	I: singleton pregnancy and presented prior to 20 w. E: Major fetal anomaly, HIV positive, history of organ transplant, chronic steroid use.	28.6 (+/- 6.3)	Not reported.	Recto- vaginal swabs followed by culture detection per CDC guidelines	GDM diagnostic criteria and differences in severity of disease may impact findings.	Low



	G	DM	Co	ntrol		Odds Rat	io	Weight
Study	GBS+	GBS-	GBS+	GBS-		(95% CI)	(%)
Pregestational diabetes prevalence indeterminate								
Medugu, 2017	11	7	160	322		2.40 (0.82,	7.02)	0.54
Chen, 2018	51	832	159	2397	-	0.92 (0.67,	1.27)	4.89
Moraleda, 2018	5	13	77	254		1.27 (0.44,	3.67)	0.55
Dai, 2019	в	18	40	314		3.49 (1.42,	8.54)	0.77
Ji, 2019	39	908	228	8685		1.60 (1.13,	2.26)	4.38
Zhu, 2019	1243	7064	5690	35911	•	1.11 (1.04,	1.19)	21.44
Alfouzan, 2021	в	21	21	95		1.72 (0.67,	4.42)	0.70
Huang, 2021	41	27	79	93		1.79 (1.01,	3.16)	1.81
I-squared = 67.8%, p = 0.02					•	1.43 (1.08,	1.90)	
Pregestational diabetes prevalence documented								
Matorras, 1988	7	26	107	873		2.20 (0.93,	5.18)	0.84
Raimer, 1997	4	39	3	98		3.35 (0.72, 1	5.66)	0.26
Ramos, 1997	20	37	68	232		1.84 (1.00,	3.39)	1.61
Piper, 1999	55	391	125	921		1.04 (0.74,	1.45)	4.55
Stapleton, 2005	1310	2780	32584	70248	•	1.01 (0.90,	1.13)	16.65
Edwards, 2019	559	1515	11937	44204	٠	1.21 (1.11,	1.32)	19.42
Furfaro, 2019	21	66	111	342		0.98 (0.57,	1.68)	2.04
Manzanares, 2019	122	466	1695	7531	*	1.16 (0.95,	1.43)	9.39
Place, 2021	182	572	282	913	•	1.03 (0.83,	1.28)	8.97
Del Carmen Palacios-Saucedo, 2022	2	209	15	907 -		0.58 (0.13,	2.55)	0.29
McCoy, 2023	11	13	151	305		1.71 (0.75,	3.91)	0.90
I-squared = 27%, p = 0.10					*	1.13 (1.03,	1.24)	
Overall						1.16 (1.07,	1.26)	
I-squared = 34.9%, p = 0.02					£			
				0.13	1 2 4 8	16		
Pandom offects PEMI model								

Random-effects REML model

	Pregestal	tional DI	M Co	introl				Odds	Ratio	Weight
Study	GBS+	GBS-	GBS+	GBS-				(95%	CI)	(%)
Matorras, 1988	7	30	107	873			•	1.90 (0.82	4.44)	8.87
Raimer, 1997	4	51	3	98				2.56 (0.55	6, 11.89)	3.81
Ramos, 1997	26	22	68	232				4.03 (2.15	, 7.56)	12.00
Stapleton, 2005	194	371	32,584	70,248				1.13 (0.95	. 1.34)	20.03
Edwards, 2019	458	1,294	11,937	44,204			•	1.30 (1.17	(1.45)	20.73
Furfaro, 2019	8	19	111	342		-	•	1.30 (0.55	, 3.05)	8.79
Manzanares, 2019	18	45	1,695	7,531			-0-	1.78 (1.03	, 3.08)	13.38
Place, 2021	5	5	282	913			•	3.24 (0.93	, 11.26)	5.28
Del Carmen Palacios-Saucedo, 2022	0	21	15	907	_		•	1.35 (0.08	. 23.50)	1.27
McCoy, 2023	7	5	151	305			•	2.83 (0.88	9.06)	5.84
Overall							+	1.76 (1.23	2.45)	
I-squared = 78.5%, p = .01										
					.13	0.5	2 1	8 24		
Random-effects REML model										

	Pregestati	ional DM	A G	DM					Odds R	atio	Weight
Study	GBS+	GBS-	GBS+	GBS-					(95%)	CI)	(%)
Matorras, 1988	7	30	7	26		-		(.87 (0.27,	2.80)	4.57
Raimer, 1997	4	51	4	39		-		(.76 (0.18,	3.25)	3.16
Ramos, 1997	26	22	20	48		-	-	1	.84 (1.31,	6.13)	8.87
Stapleton, 2005	194	371	1,310	2,780				- 8	.11 (0.92,	1.34)	27.29
Edwards, 2019	456	1,294	559	1,515					.96 (0.83,	1.10)	28.75
Furfaro, 2019	8	19	21	66				1	.32 (0.51.	3.46)	6.35
Manzanares, 2019	18	45	122	466		-		1	.53 (0.85,	2.73)	12.82
Place, 2021	5	5	182	572		+	-		1.14 (0.90,	10.98)	4.09
Del Carmen Palacios-Saucedo, 2022	0	21	2	209				- 1	.95 (0.09,	41.92)	0.76
McCoy, 2023	7	5	11	13				1	.65 (0.41,	6.71)	3.35
Overall						٠		1	.26 (0.96,	1.66)	
I-squared = 55.7%, p = 0.12											
					.13	0.5 2	8	32			

Random-effects REML model

